drugset / Trial / NCT00232375

Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

NCT00232375 ↗

Completed 42 enrolled Tokyo Study Group
RandomizedParallel-groupOpen-labelPrevention

Summary

We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a preferable outcome to reverse or preserve beta cell function in the patients with diabetes that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adult (LADA).

Timeline

Start
1996-01
Primary completion
—
Completion
2005-01

Outcome

Met primary endpoint

paper insulin group (three of 30, 10%) was lower than that in the SU group (13 of 30, 43%; P = 0.003, log-rank). PMID 18397986 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic — —

Indications

No indication recorded.